Karen Ling Net Worth

The estimated Net Worth of Karen Ling is at least $8.16 mil dollars as of 18 August 2022. Ms. Ling owns over 1,984 units of TherapeuticsMD stock worth over $8,162 and over the last 9 years she sold TXMD stock worth over $0. In addition, she makes $0 as Independent Director at TherapeuticsMD.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Ling TXMD stock SEC Form 4 insiders trading

Karen has made over 7 trades of the TherapeuticsMD stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 1,984 units of TXMD stock worth $3,527 on 18 August 2022.

The largest trade she's ever made was exercising 96,864 units of TherapeuticsMD stock on 10 August 2021 worth over $172,215. On average, Karen trades about 4,193 units every 26 days since 2016. As of 18 August 2022 she still owns at least 4,591 units of TherapeuticsMD stock.

You can see the complete history of Ms. Ling stock trades at the bottom of the page.

Karen Ling biography

Karen Lee Ling J.D. serves as Independent Director of the Company. Ms. Ling has served as Executive Vice President and Chief Human Resources Officer at American International Group, Inc. [NYSE: AIG] since July 2019. From March 2015 until July 2019, she served as Executive Vice President and Chief Human Resources Officer at Allergan plc [NYSE: AGN], a global pharmaceutical company. From July 2014 until March 2015, Ms. Ling served as Senior Vice President, Human Resources and Chief Human Resources Officer at Actavis plc, a global pharmaceutical company, prior to its acquisition of Allergan and name change to Allergan. From January 2014 until July 2014, Ms. Ling was Senior Vice President and Chief Human Resources Officer at Forest Laboratories, a company which was focused on licensing European pharmaceuticals for sale in the United States, prior to its acquisition by Actavis. Prior to this, from 2011 until January 2014, Ms. Ling was Senior Vice President, Human Resources of the Global Human Health and Consumer Care businesses worldwide for Merck & Co., Inc. [NYSE: MRK]. She also served as Vice President, Global Compensation and Benefits, at Merck from November 2009 until 2011. Ms. Ling received a B.A. in Economics from Yale University and a J.D. from Boston University, and is admitted to practice law in New York and Massachusetts.

How old is Karen Ling?

Karen Ling is 56, she's been the Independent Director of TherapeuticsMD since 2020. There are 8 older and 17 younger executives at TherapeuticsMD. The oldest executive at TherapeuticsMD, Inc. is Tommy Thompson, 78, who is the Independent Chairman of the Board.

What's Karen Ling's mailing address?

Karen's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.

Insiders trading at TherapeuticsMD

Over the last 13 years, insiders at TherapeuticsMD have traded over $60,334,483 worth of TherapeuticsMD stock and bought 3,746,989 units worth $33,644,571 . The most active insiders traders include Cooper C. Collins, Brian Bernick, eRobert G Finizio. On average, TherapeuticsMD executives and independent directors trade stock every 30 days with the average trade being worth of $233,918. The most recent stock trade was executed by Cooper C. Collins on 22 August 2024, trading 4,094 units of TXMD stock currently worth $7,083.

What does TherapeuticsMD do?

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Complete history of Ms. Ling stock trades at iRhythm Technologies Inc, American International Inc, Mallinckrodt Plc, eTherapeuticsMD

TherapeuticsMD executives and stock owners

TherapeuticsMD executives and other stock owners filed with the SEC include:

• John Milligan,
  President, Secretary
• Brian Bernick,
  Co-Founder
• Robert Finizio,
  Chief Executive Officer and Director
• Robert G. Finizio,
  Co-Founder & Vice Chair
• Mitchell Krassan,
  Chief Strategy and Performance Officer
• John C. K. Milligan IV,
  Chief Exec. Officer of VitaCare Prescription Services
• Michael Donegan,
  Vice President - Finance
• Tommy Thompson,
  Independent Chairman of the Board
• Cooper Collins,
  Independent Director
• J. Martin Carroll,
  Independent Director
• Angus Russell,
  Independent Director
• Jules Musing,
  Independent Director
• Dr. Brian A. Bernick,
  Co-Founder & Chief Scientific Officer
• Nichol Ochsner,
  Vice President, Investor Relations
• Gail Naughton,
  Independent Director
• Karen Ling,
  Independent Director
• Paul Bisaro,
  Independent Director
• Bharat Warrier,
  Chief Manufacturing Officer
• Sebastian Mirkin,
  Chief Medical Officer
• Dawn Halkuff,
  Chief Commercial Officer
• Marlan Walker,
  General Counsel
• John Knighton,
  Chief Compliance Officer
• Adam Miller,
  Chief Information Officer
• James D'Arecca,
  Chief Financial Officer
• Julia M. Amadio,
  Chief Product Officer
• Mitchell L. Krassan,
  Exec. VP and Chief Strategy & Performance Officer
• Michael Donegan,
  Chief Accounting Officer & VP of Fin.
• James C. D'Arecca,
  Chief Financial Officer
• Hugh O'Dowd M.B.A.,
  Pres, CEO & Director
• Robert V Jr La Penta,
  Director
• Nicholas Segal,
  Director
• Daniel A Cartwright,
  Chief Financial Officer
• Capital Management Lp Rosen...,
  
• Jane F Barlow,
  Director
• Samuel A Greco,
  Director
• Randall S Stanicky,
  Director
• Edward Borkowski,
  EVP, Operations
• Hugh O'dowd,
  Chief Executive Officer
• Mark A Glickman,
  Co-Chief Executive Officer
• Joseph Ziegler,
  Principal Financial Officer